Lilly Focuses On ‘Traditional’ Approval For Donanemab, Increased Mounjaro Production
Executive Summary
Mounjaro’s fourth quarter sales disappointed some analysts, but the launch remains off to a strong start. Donanemab now on track for full approval in Alzheimer’s, CEO Ricks pledges.
You may also be interested in...
A Lesson In Confidence Amid Development Hurdles: How Lilly Has Talked About Donanemab
The Alzheimer’s disease candidate’s positive milestones, and even its review delays, continue to produce confident statements in its future from the sponsor.
Lilly Sales Swing Back As Pandemic, Loss Of Exclusivity Pressures Recede
The drug maker is looking ahead to potentially big approvals of donanemab for Alzheimer’s disease and Mounjaro for obesity by the end of the year.
Lilly’s Donanemab Slows Cognitive Decline; FDA Filing Imminent
The company’s anti-amyloid antibody succeeded in Phase III with efficacy at least on par with Eisai/Biogen’s Leqembi, but with ARIA-related deaths unseen with the rival therapy.